News
Food and Drug Administration Commissioner Marty Makary has taken a personal interest in addressing hormone therapy treatment ...
2d
Her Agenda on MSNF.D.A. Discusses Removal Of Most Severe Warning On Menopause TreatmentsAt a recent U.S. Food and Drug Administration (F.D.A.) panel, doctors argued for the removal of the black box warning on hormone treatments used to alleviate menopause symptoms. The black box warning ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Memo warns GOP not to let ObamaCare tax ...
The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...
The contrast between the FDA’s clinical lens and the raw realities in the Bonafide study highlights a critical disconnect ...
A Food and Drug Administration (FDA) expert panel has reignited a debate over whether hormone therapy should be used to treat ...
A new study suggests that hormone therapy, often used to ease symptoms of menopause like hot flashes and night sweats, may ...
A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...
US health authorities are reassessing the risks of Hormone Replacement Therapy (HRT) in a meeting convened by FDA chief Marty ...
A groundbreaking study of nearly 45,000 people shows how a blood test measuring proteins can estimate which organs are aging ...
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.
“The TRE-515 FDA designation offers continued hope to the mCRPC community.” Dr. Czernin coinvented an FDA approved PSMA targeting probe for prostate cancer in 2020.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results